These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8915518)

  • 1. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
    Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.
    Marches R; Mota G; Margineanu M; Stavri H; Savi G; Nicolae M; Bancu A; Moraru I
    Neoplasma; 1990; 37(5):573-8. PubMed ID: 2234217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 enhances the efficiency of immunotoxins in the treatment of mice with ascitic tumors.
    Margineanu M; Marches R; Dima S; Cialacu V; Kozma E; Savi G; Stavri H; Badea E; Bancu A; Mota G
    Neoplasma; 1991; 38(6):633-8. PubMed ID: 1766487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
    Blakey DC; Watson GJ; Knowles PP; Thorpe PE
    Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
    Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
    Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE; Johnson DE; Shawler DL; Dillman RO
    Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
    Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
    J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Jan; 44(1):201-8. PubMed ID: 6140077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.